Chardan Capital Has Weak Forecast for DYN FY2024 Earnings

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Stock analysts at Chardan Capital dropped their FY2024 earnings per share estimates for shares of Dyne Therapeutics in a research report issued on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($3.14) for the year, down from their prior forecast of ($2.75). Chardan Capital currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.39) per share. Chardan Capital also issued estimates for Dyne Therapeutics’ FY2025 earnings at ($2.73) EPS.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25).

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $43.00 to $35.00 in a research report on Thursday, October 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Morgan Stanley lifted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Finally, Guggenheim boosted their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $51.40.

Dyne Therapeutics Stock Performance

Shares of Dyne Therapeutics stock opened at $28.39 on Monday. The stock has a 50 day moving average of $32.48 and a 200 day moving average of $35.24. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -7.97 and a beta of 1.10. Dyne Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $47.45.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its stake in shares of Dyne Therapeutics by 4.3% during the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock worth $300,000 after acquiring an additional 352 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Dyne Therapeutics by 24.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares in the last quarter. KBC Group NV grew its holdings in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after purchasing an additional 751 shares during the last quarter. Finally, Amalgamated Bank increased its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after buying an additional 796 shares in the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the acquisition, the chief executive officer now directly owns 8,000 shares of the company’s stock, valued at approximately $264,320. The trade was a -133.33 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This trade represents a 25.33 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 158,975 shares of company stock worth $5,693,789. 20.77% of the stock is owned by insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.